 |
|
|
|
 |
|
|
| Article 1 to 10 out of 93 concerning Crucell N.V.
|
-
DSM and Crucell Sign Agreement with Avid Bioservices to Serve as U.S. Contract Manufacturer of PER.C6 Cell Line Proteins
(06/26/2008)
DSM Biologics and Crucell N.V. announced that they have entered into an agreement with Avid Bioservices, Inc. of Tustin, California to join their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved contract manufacturer ...
-
DSM and Crucell Announce Record Achievement in PER.C6 Technology
(06/17/2008)
DSM Biologics and Crucell N.V. announced a breakthrough in the production of IgG antibodies using PER.C6® technology. By employing the PER.C6® human cell line and proprietary XD(TM) technology, a record yield of over 27 grams per liter has been ...
-
Crucell Announces Research License Agreement with Bioceros on STAR Technology
(05/21/2008)
Crucell N.V. announced a non-exclusive STAR® research license agreement with Bioceros. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. Financial details of the agreement were not ...
-
Crucell: Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines
(05/15/2008)
Crucell N.V. announced that its rabies monoclonal antibody combination product has entered a second phase II clinical study in the Philippines. On 31 March 2008 the company announced the start of a first phase II clinical study in the U.S.The second ...
-
Crucell Announces STAR Research License Agreement with Toyobo Gene Analysis Co. LTD.
(05/05/2008)
Crucell N.V. announced a non-exclusive STAR® research license agreement with Toyobo Gene Analysis Co. LTD. Under the agreement, Toyobo Gene Analysis will evaluate Crucell's STAR® technology for generating cell lines for the production of recombinant ...
-
Aeras, Crucell and SATVI Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
(04/11/2008)
Crucell N.V., the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative (SATVI) presented a progress update and immunology data from a Phase I Ad35 tuberculosis vaccine study at the biennial "Tuberculosis Vaccines ...
-
Crucell Announces STAR Research License Agreement with Celltrion, Inc.
(04/10/2008)
Crucell N.V. announced a non-exclusive STAR® research license agreement with Celltrion, Inc. for the production of recombinant proteins. Under the agreement, Celltrion will evaluate Crucell's STAR® technology for generating cell lines for the ...
-
Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
(04/03/2008)
First Milestone Achieved in Collaboration Agreement with Sanofi Pasteur
Crucell N.V. announced that its rabies monoclonal antibody combination has entered a Phase II clinical trial in the United States. At the beginning of the year, Crucell announced it had signed a collaboration and commercialization agreement with ...
-
DSM and Crucell Announce PER.C6 Technology Milestone
(03/13/2008)
DSM Biologics, a business unit of DSM Pharmaceutical Products and Crucell N.V. announced that another important milestone has been achieved with the PER.C6® technology platform for the production of monoclonal antibodies and recombinant proteins. ...
-
Crucell Reacts to Recent CEVEC Press Release
(01/18/2008)
Crucell N.V. reacted to a press release issued by German company CEVEC Pharmaceuticals GmbH. In their press release CEVEC announced that one of Crucell's PER.C6® patents for protein production was restricted by a recent decision of the European ...
Additional information
Crucell N.V.
Leiden, Netherlands
Company
|
|
|
|
|
|
Top
